A European AI factory is being built at Forschungszentrum Jülich. The ExaFlops supercomputer JUPITER is getting a third ...
Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the ...
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers. On track for commercial launch in the U.S. in ...
“We feel with the victims, we are praying for the victims — we hope very much that they all make it," Bavarian governor Markus Söder told reporters at the scene. “It is suspected to be an attack — a ...
US expected to increase biodefence spending under Trump, says vaccine maker Bavarian Nordic Vaccine maker Bavarian Nordic expects the incoming Trump administration to boost biodefence funding ...